Chinese journal of natural medicinesOct 28, 2026

Icariin’s potential to reduce brain inflammation by affecting gut bacteria, nerve signals, and cell-to-cell messengers

Gut-Brain Axis Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 29, 2026

Abstract

Icariin, a flavonoid glycoside from Epimedii Folium, shows promise in combating neuroinflammation through various interconnected biological pathways.

Neuroinflammation is linked to multiple central nervous system disorders, and single-target therapies have limited success.
Gut-brain axis dysfunction may worsen neuroinflammation through metabolic, immune, neural, and vesicle-associated mechanisms.
Icariin is associated with protective effects on the intestinal barrier and modulation of gut microbiota.
Evidence suggests icariin may help suppress peripheral cytokines and regulate central inflammatory pathways.
The roles of short-chain fatty acid signaling, vagal communication, and extracellular vesicles in this context remain plausible but not fully validated.
Major limitations include a lack of causal evidence, incomplete pharmacokinetic data, and variability in individual microbiota profiles.

Simplified

Neuroinflammation is a central pathological process in a wide range of central nervous system disorders, yet therapeutic strategies directed solely at single inflammatory targets have shown limited efficacy. Gut-brain axis dysfunction may contribute to neuroinflammatory progression through interconnected metabolic, immune, neural, and vesicle-associated routes. Icariin, a major flavonoid glycoside from Epimedii Folium, has attracted attention because of its anti-inflammatory, neuroprotective, and microbiota-modulating properties. In this review, we summarize current evidence for the anti-neuroinflammatory effects of icariin and explicitly stratify the evidence into three levels: direct icariin-related findings, icariin-related findings without causal gut-brain validation, and mechanisms inferred from broader gut-brain axis biology. Available studies provide relatively stronger support for intestinal barrier protection, microbiota remodeling, peripheral cytokine suppression, and central inflammatory pathway regulation. In contrast, short-chain fatty acid (SCFA)-associated signaling, vagal neuroimmune communication, and extracellular vesicle (EV)-mediated cargo transfer remain plausible but incompletely validated candidate routes. We further compare icariin with its major microbial metabolites, especially icariside II and icaritin, because oral icariin may act partly through metabolite-mediated exposure rather than through robust brain penetration of the parent compound. Major limitations include insufficient causal perturbation, incomplete organ-specific pharmacokinetic data, inter-individual microbiota variability, and uncertain therapeutic time windows. Overall, icariin emerges as a promising multi-target natural product for anti-neuroinflammatory research, but the causal hierarchy and translational relevance of proposed gut-brain pathways require direct validation.

Full Text

Full text is available at the source.

View Full Text ↗

Icariin’s potential to reduce brain inflammation by affecting gut bacteria, nerve signals, and cell-to-cell messengers

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the gut-brain axis brief